Laurence H Klotz1. 1. Division of Urology, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Many newly diagnosed patients with prostate cancer have "good risk" disease. The challenge is to identify the minority of these patients with aggressive disease and offer them curative treatment, while sparing the remainder the morbidity of unnecessary treatment. PURPOSE: To examine the results of active surveillance with selective delayed intervention in good risk prostate cancer patients. MATERIALS AND METHODS: This was a prospective phase II study of active surveillance of 299 patients. Eighty percent (239 patients) met the criteria for good risk disease: PSA < 10 ng/mL, Gleason < 6, T < 2a. Twenty percent of patients, all of whom who were age 70 or greater, had Gleason 7 cancer or a PSA above 10. RESULTS: At 8 years, overall survival is 85% and disease-specific survival is 99%. A PSA doubling time of < 2 years was linked with likelihood of locally advanced disease. CONCLUSION: Watchful waiting is clearly appropriate for elderly prostate cancer patients with high co-morbidities. For good risk, young, healthy patients, this study supports the feasibility of long-term, close monitoring with early intervention for those who progress rapidly. Approximately two thirds of such patients will remain free of treatment over 8 years.
BACKGROUND: Many newly diagnosed patients with prostate cancer have "good risk" disease. The challenge is to identify the minority of these patients with aggressive disease and offer them curative treatment, while sparing the remainder the morbidity of unnecessary treatment. PURPOSE: To examine the results of active surveillance with selective delayed intervention in good risk prostate cancerpatients. MATERIALS AND METHODS: This was a prospective phase II study of active surveillance of 299 patients. Eighty percent (239 patients) met the criteria for good risk disease: PSA < 10 ng/mL, Gleason < 6, T < 2a. Twenty percent of patients, all of whom who were age 70 or greater, had Gleason 7 cancer or a PSA above 10. RESULTS: At 8 years, overall survival is 85% and disease-specific survival is 99%. A PSA doubling time of < 2 years was linked with likelihood of locally advanced disease. CONCLUSION: Watchful waiting is clearly appropriate for elderly prostate cancerpatients with high co-morbidities. For good risk, young, healthy patients, this study supports the feasibility of long-term, close monitoring with early intervention for those who progress rapidly. Approximately two thirds of such patients will remain free of treatment over 8 years.
Authors: Ramachandran Venkitaraman; Karen Thomas; Phillip Grace; David P Dearnaley; Alan Horwich; Robert A Huddart; Christopher C Parker Journal: Tumour Biol Date: 2010-02-16
Authors: Christopher J Kane; Ronald Im; Christopher L Amling; Joseph C Presti; William J Aronson; Martha K Terris; Stephen J Freedland Journal: Urology Date: 2010-04-15 Impact factor: 2.649
Authors: M Schenck; K Krause; R Schwandtner; I Haase; D Fluehs; J Friedrich; T Jaeger; C Boergermann; H Ruebben; M Stuschke Journal: Urologe A Date: 2006-06 Impact factor: 0.639
Authors: Baris Turkbey; Vijay P Shah; Yuxi Pang; Marcelino Bernardo; Sheng Xu; Jochen Kruecker; Julia Locklin; Angelo A Baccala; Ardeshir R Rastinehad; Maria J Merino; Joanna H Shih; Bradford J Wood; Peter A Pinto; Peter L Choyke Journal: Radiology Date: 2010-12-21 Impact factor: 11.105
Authors: Mats Steinholtz Ahlberg; Hans-Olov Adami; Kerri Beckmann; Helena Bertilsson; Ola Bratt; Declan Cahill; Lars Egevad; Hans Garmo; Lars Holmberg; Eva Johansson; Antti Rannikko; Mieke Van Hemelrijck; Fredrik Jäderling; Cecilia Wassberg; Ulrika W N Åberg; Anna Bill-Axelson Journal: BMJ Open Date: 2019-08-22 Impact factor: 2.692